Search bioRxiv⌕ Search

bioRxiv · 10.1101/2025.09.11.675514

FERROPTOSIS GENE SIGNATURES REVEAL DISTINCT REGULATORY LANDSCAPES IN GASTRIC ADENOCARCINOMA AND OTHER TISSUES

Abstract

BackgroundGastric adenocarcinoma (GAC) remains one of the most lethal malignancies worldwide, with late-stage diagnosis and limited therapeutic options. Ferroptosis, a regulated form of cell death driven by iron-dependent lipid peroxidation, has emerged as a promising target for overcoming tumor resistance mechanisms. This study aimed to characterize the transcriptional landscape of ferroptosis-related genes in GAC, comparing tumor, peritumoral, metaplastic, and normal gastric tissues. MethodsRNA-Seq was performed on 385 biopsied samples from patients treated at the Joao de Barros Barreto University Hospital. Differential expression analysis was conducted using DESeq2, and genes related to ferroptosis were identified based on FerrDb V2 annotations. Visualization included volcano plots, DAPC clustering, heatmaps, and gene dominance scoring. ResultsGAC samples showed a distinct ferroptotic expression signature, with simultaneous upregulation of key promoters (e.g., CDKN2A, NOX4, EGFR, IL6) and suppressors (e.g., HSPB1, SCD, NUPR1, GDF15). Notably, the tumor tissue exhibited a net dominance of ferroptosis-inhibitory genes, suggesting an adaptive response to oxidative stress. Adjacent tissues showed partial overlap with tumor profiles, while metaplastic tissue displayed a hybrid signature with selective suppression of ferroptosis. Normal mucosa exhibited dominant expression of promoters, contrasting with the tumors anti-ferroptotic phenotype. ConclusionThe transcriptional heterogeneity and regulatory imbalance of ferroptosis-related genes in GAC support its role as a potential therapeutic axis. These findings provide molecular insights for biomarker discovery and ferroptosis-targeted strategies in gastric cancer.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Ramos, S. A. A., de Abreu, T. P., da Conceicao, M., Santos da Silva, V. C., Pereira, D., Avelar, D. d. S., da Silva, J. M. C., Mourao, R. M. d. S., da Silva, R. F., Barra, W. F., Moraes Casseb, S. M., dos Santos, A. K. C. R., Demachki, S., Ishak, G., Moreira, F. C., Burbano, R. M. R., de Assumpcao, P. P.. 2025-09-16. FERROPTOSIS GENE SIGNATURES REVEAL DISTINCT REGULATORY LANDSCAPES IN GASTRIC ADENOCARCINOMA AND OTHER TISSUES. https://doi.org/10.1101/2025.09.11.675514

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Sisyphus at the splenic flexure: sidedness in colorectal cancer

Colorectal cancer is divided into left and right to guide prognosis and therapy, yet a precise definition of left vs right sided colorectal cancer is still not fully agreed upon. The published conventions place it anywhere between the cecum and the rectosigmoid junction. The dichotomy assumes side homogeneity, i.e., that colorectal subsites within a side add limited information once the side is known. That assumption has been examined primarily through mutation prevalence, a quantity that confounds how often a driver arises with how strongly it is selected once it has. Analyzing 1,027 whole-exome and whole-genome sequenced colorectal tumors, we decomposed the prevalence of six driver groups into mutation supply and cancer effect, and asked whether a binary side label captures how each of their prevalence, mutation supply, and cancer effect vary along the colorectum. Mostly it does: the mutational input behaves as two blocks, and even the more than thirty-fold strengthening of cancer effect on BRAF V600E from sigmoid colon to cecum is adequately captured by side. But APC shows nominal evidence against side homogeneity in both prevalence and cancer effect while showing little net left-right difference, and PIK3CA H1047 rejects it in supply. The evidence for finer resolution is real but partial, and the failures do not announce themselves. We recommend additional research recording primary tumor location at the finest practicable resolution--at minimum, International Classification of Diseases for Oncology, 3rd Edition (ICD-O-3) topography. Such well-annotated datasets would enable the left-right boundary to be a reversible analytic choice rather than an irreversible annotation.

cancer biology↗

GATA2 SUMOylation Regulates GATA2 Stability to Control Uterine Serous Carcinoma Invasion

Uterine serous carcinoma (USC) is an aggressive uterine cancer subtype that rapidly invades the uterine myometrium and is responsible for 40% of uterine cancer deaths. The molecular mechanisms that underlie this aggressive phenotype are poorly understood. We reported recently that USC tumors with low expression of the zinc-finger transcription factor GATA Binding Protein 2 (GATA2) exhibit aggressive tissue invasion, while retention of GATA2 expression is an independent predictor of 100% recurrence-free and cancer-specific survival in patients with early-stage USC. Here, we explored the mechanism of GATA2 loss in USC tumors that portend invasion. We show that GATA2 in human USC cell lines has a rapid 128-minute protein half-life due to post-translational SUMOylation, which targets GATA2 for ubiquitin-dependent proteasomal degradation. Treatment with small-molecule SUMOylation inhibitors, siRNA-mediated depletion of SUMO-2/3, or mutation of GATA2 K222 and K389 increases GATA2 levels and suppresses invasion in USC cell lines and USC tumor spheroids without impacting cell proliferation or viability. Primary USC tumors from newly diagnosed patients show markedly increased SUMO-2/3 levels and upregulation of SUMOylation pathways compared to other uterine cancer subtypes or benign endometrium, and heat-shock mediated induction of USC SUMO signaling leads to a SUMOylation-dependent reduction in GATA2 levels. Our results implicate SUMOylation as a dynamic regulator of USC GATA2 levels and support a model in which stress-related increases in SUMO activity deplete GATA2 to drive USC invasion. Our findings also raise the possibility that small-molecule SUMOylation inhibitors may benefit patients with early-stage USC disease.

cancer biology↗

SLC25A39 loss disrupts mitochondrial redox homeostasis and exposes therapeutic vulnerabilities in glioblastoma

Glioblastoma is an incurable brain tumour characterised by extensive hypoxia and phenotypic plasticity, both of which drive therapy resistance. Mitochondrial glutathione, dependent on the inner membrane carrier SLC25A39, is central to buffering the oxidative stress that hypoxia generates; its regulation and significance in glioblastoma are nonetheless unknown. We find that SLC25A39 expression is hypoxia-inducible and HIF-dependent, enriched in hypoxic tumour niches and heterogeneously expressed within and between tumours. Its loss depletes mitochondrial glutathione, causing oxidative damage to nucleic acids and lipids, mitochondrial hyperfusion, impaired respiration and a compensatory shift towards glycolysis, glutamine catabolism and serine synthesis. SLC25A39-deficient cells grow poorly, yet resist temozolomide while becoming markedly sensitive to navitoclax, an inhibitor of Bcl-2 and Bcl-xL, which increases cell killing when combined with radiation and temozolomide. In this work, we identify SLC25A39 as a metabolic vulnerability and candidate stratification marker in glioblastoma.

cancer biology↗